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Abstract A novel rat /x opioid receptor (rMOR1B) has been 
isolated. It shows identity to the recently published sequence of 
rMOR1 [Chen, et al., Mol. Pharmacol., 44 (1993) 8-12] up to 
amino acid 386 and differs only in length and amino acid compo- 
sition at the very carboxy-terminal tail. Both/z opioid receptor 
isoforms, when stably expressed in CHO-K1 cells, show similar 
affinities to opioid compounds and are equally effective in the 
inhibition of forskolin-induced cAMP formation. Reverse tran- 
scription polymerase chain reaction (RT-PCR) revealed that 
rMORIB displays a similar distribution as rMOR1 in various rat 
brain areas. Studies measuring the inhibition of adenylate cyclasc 
in cells that had been pre-exposed to the /t opioid agonist 
DAMGO indicated that rMORIB is much more resistant to 
agonist-induced esensitization than rMOR1. 
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1. Introduction 
Opioids exert their effects by specifically interacting with 
receptors which are widely distributed throughout he central 
and peripheral nervous system [1]. Until now, three subtypes 
of opioid receptors, termed/1 [2~], ~ [4-6] and I¢ [7-12], have 
been cloned. They belong to the families of membrane recep- 
tors that transduce their intracellular signals via G protein- 
coupled pathways [13-15], and mediate the inhibition of 
adenylate cyclase, activation of  potassium channels and/or inhi- 
bition of calcium channel activity through a pertussis-toxin- 
sensitive mechanism [13,16]. Most interesting among them is 
the/1 receptor, because this receptor is thought to play an 
important role in mediating the opioid phenomena classically 
associated with morphine, including analgesia, opioid depend- 
ence and tolerance, and respiratory functions. In the present 
study, we report the cloning of a rat cDNA (rMOR1B) which 
shares sequence identity to the rat /1 opioid receptor up to 
amino acid 386. This cDNA,  which is very likely produced by 
alternative splicing, varies from rMOR1 in length and amino 
acid composition only at the C-terminal tail. Further, it is 
reported that both isoforms have similar binding properties and 
are equally effective in inhibiting forskolin-stimulated cAMP 
production. However, we demonstrate that rMOR1B is much 
more resistant to agonist-induced desensitization than rMOR 1. 
2. Materials and methods 
2.1. Cloning of cDNA 
A mouse opioid receptor cDNA fragment was isolated by polym- 
erase chain reaction (PCR) from reverse transcribed (RT) mRNA iso- 
lated from (NG108-15) cells using the following primers: 
AGACCGCCACCAACATCTACAT (sense), and CCCACCAC- 
CACCAGCACCAT (antisense), corresponding totransmembrane do- 
mains I and VI, respectively. Cycle conditions were: 1 min at 96°C, 
1 min at 60°C and 1 min at 72°C for 40 cycles. The ends of the resulting 
product (562 bp) were filled in with Klenow enzyme and cloned into 
the EcoV site of pBluescript SK(-) (Stratagene). This fragment was 
then used to screen 1 × 10 6 plaques from a rat brain cDNA library 
(1 ZAP II; Stratagene) under low stringency conditions (20% forma- 
mide, 5 x SSC (1 x SSC = 0.15 M sodium chloride; 0.015 M sodium 
citrate), 5x Denhardt solution, 100 ~g/ml salmon sperm DNA, at 37°C 
overnight). Filters were washed in 2 x SSC at 37°C for 2 h. Plasmids 
were autoexised from positive phage DNA. One 2.4 kb clone 
(rMOR1B) was sequenced and further characterized. 
2.2. DNA transfection fCHO-K1 cells and binding analysis 
A StuI-XbaI fragment of rMOR1B, containing the entire protein- 
coding sequence, was cloned into pcDNAI.neo (Invitrogen). rMOR1 
cloned into pRc/CMV was kindly provided by Dr. Lei Yu (Indianapo- 
lis, USA). For stable expression, CHO-K1 cells were grown to 50% 
confluency in a 35 mm dish and subsequently transfected with the 
receptor expression plasmids using lipofeetin (Gibco/BRL) according 
to the instructions of the manufacturers. Stable transfectants were se- 
lected in NUT-F12 medium containing 10% FCS (fetal calf serum) and 
600/lg G418 (Gibco/BRL) per ml, and checked for expression by 
Northern blot analyses. For binding studies, cells were grown to conflu- 
ency and the membranes prepared as described [2]. For competitive 
binding studies, cell membranes (15-50/tg protein; measured by a 
protein assay kit (Bio-Rad)) were incubated with 2 nM [3H]DAMGO 
(D-ala 2, N-methyl-phe 4, glyol enkephalin) inthe presence of a competing 
ligand for 30 min at 25°C in a final volume of 500/ll. All assays were 
performed in duplicate using 50 mM Tris-HCl, pH 7.4, and 0.2% BSA 
(bovine serum albumin). The reactions were terminated by vacuum 
filtration through Whatman GF/B filters that had been pretreated with 
1% polyethylenimine. Non-specific binding was determined using 10 
/tM DAMGO. 
2.3. RT-PCR 
Total RNA was isolated from tissues of adult Wistar rats as de- 
scribed [17], digested with RQ1 RNase-free DNase (Promega) and 
converted to single-stranded cDNA by priming of 2/~g total RNA with 
hexanucleotide primers and reverse trancriptase (Superscript; BRL). 
cDNAs were amplified using Taq polymerase (Pharmacia) and up- and 
downstream primers PMOR-1, PMOR-2 and PMOR-3, as indicated in 
Fig. 1 for 35 cycles (96°C for 1 min, 55°C for 1 min, and 72°C for 
2 min). To test the conditions for the PCR reaction, cDNAs were 
subjected to 30, 35, 38 or 40 cycles of amplification. Saturation was 
observed after 38 and 40 rounds of amplification. The resulting prod- 
ucts for rMOR1 (404 bp) and rMOR1B (364 bp) were electrophoresed 
and stained with ethidium bromide. 
*Corresponding author. Fax: (49) (391) 672 869. 
2.4. Adenylate cyclase xperiments 
Accumulation of cAMP was measured as follows: 1.5 x 105 stable 
transfected CHO-K1 cells were seeded in 22 mm twelve-well dishes with 
NUT-F12 medium containing 10% FCS. cAMP assays were performed 
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24 h later. Cells were washed twice with serum-free medium (SFM) and 
pretreated with SFM containing 200 pM isobutyl methyl xanthine for 
20 min at 37°C. Thereafter, forskolin (25/tM final concentration) or 
a combination of forskolin and DAMGO were added at the indicated 
concentration a d the incubation continued for 15 min at 37°C. The 
reaction was terminated by removing the medium, scraping and soni- 
cating the cells in 1 ml of ice-cold HC1/EtOH (1 vol. of 1 N HCI/100 
vols. EtOH). After evaporation of the solution, the residue was dis- 
solved in 10 mM Tris, 1 mM EDTA (TE) buffer (pH 7.4), and cAMP 
content measured using a commercially available kit (Amersham; TRK 
432). For time-course experiments, cells were seeded as described above 
and DAMGO (1 gM) was added into the growth media t 37°C at the 
indicated times before assay. For some studies cells were incubated with 
pertussis toxin (PTX, 100 ng/ml) (List Biological Laboratories Inc.) for 
24 h before assay. 
3. Results 
3.1. Cloning of  the cDNA 
A rat brain cDNA library was screened under low hybridiza- 
tion conditions with a fragment of the mouse ~ opioid receptor 
as a probe. One positive plaque contained a 2.4 kb cDNA 
fragment. Sequencing revealed that it encodes a protein of 391 
residues, which shares 100% homology with rMOR1 up to 
amino acid 386. The encoded protein is seven residues horter 
than that predicted from the rMOR1 sequence and differs in 
five amino acids at the C-terminus. The clone was therefore 
termed rMOR1B (Fig. 1). Recently the genomic organization 
of the mouse p opioid receptor was elucidated and an intron- 
exon boundary has been found between amino acids 386 and 
387 [18]. As the cDNAs of both receptors tart to differ from 
each other at exactly the same position it is very likely that 
rMOR1B, in addition to rMOR1, derives from a common 
precursor mRNA by alternative splicing. 
3.2. Expression of  receptor isoforms in CHO-K1 cells 
To test whether MOR1B differs in its binding properties 
from rMOR1, expression studies were performed. CHO-K1 
cells were stable transfected with rMOR1 and rMOR1B and 
competition binding experiments were performed using the 
/.t-specific ligand [3H]DAMGO as specific radioligand. Repre- 
sentative competition curves are shown in Fig. 2. In general, the 
relative affinities of both receptor variants for opioid ligands 
are similar. Non-labeled DAMGO displaced [3H]DAMGO 
binding with high affinity (IC50 = 5 nM), whereas the ~-selective 
agonist DPDPE [D-Pen2'5-enkephalin] and the K-selective ag- 
onist U-50488 showed low affinities, with IC50 values in the 
micromolar range. DADLE [o-ala 2, o-LeuS-enkephalin], a pre- 
dominantly 6 agonist, displayed nanomolar affinities (IC50 = 70 
nM and 100 nM, respectively). The pl-selective antagonist na- 
loxonazine also shows high affinities (IC50 = 5 nM and 6 nM, 
respectively). Taken together, these results uggests that rMOR1B 
encodes/.t receptors and that the divergence in the C-terminal 
tail does not essentially change the ligand specifities. 
3.3. RT-PCR 
RT-PCR was carried out to investigate the mRNA expres- 
sion pattern of both isoforms in various brain regions. PCR 
primers were chosen in such a way that either rMOR1 or 
rMOR1B was specifically amplified (Fig. 1). PMOR-1 and 
PMOR-2 primers were used to obtain a 404 bp fragment consis- 
tent with rMOR1 mRNA, and PMOR-1 and PMOR-3 to ob- 
tain a 364 bp fragment consistent with rMOR1B mRNA. After 
35 PCR cycles similar concentrations of amplified receptor 
mRNA levels for both rMOR1 and rMOR1B could be detected 
in various brain areas (Fig. 3). In general, the expression pat- 
tern of rMOR1 and rMOR1B mRNA in rat brain is similar, 
with highest mRNA concentrations i  the frontal cortex (lane 
2) and the striatum (lane 4) and lowest concentrationes in the 
bulbus olfactorius (lane 1) and the cerebellum (lane 10). On the 
other hand, the tegmentum (lane 9) and the pons (lane 11) 
appear to contain smaller concentrations of rMOR1B than 
rMOR1 mRNA, indicating a tissue-specific splicing. 
S T I E 359 
. . . . . . . . .  TCC ACG ATC GAA 1077 
PMOR- 1 ..... 
Q Q N S T R V R Q N T R E H P S T A N T V D R T N H Q 386 
CAG CAA AAC TCC ACT CGA GTC CGT CAG AAC ACT AGG GAA CAT CCC TCC ACG GCT AAT ACA GTG GAT CGA ACT AAC CAC CAG 1158 
. . . . . . . . . . . . . .  > 
rMOP.1 
L E N L E A E T A P L P * 398 
CTA C=AA AAT CTG GAG GCA GAA ACT GCT CCA TTG CCC TAA CTGGGTCTCACACCATCCAGACCCTCGCTAAGCTTAGAGGCCGCCATCTACGTGG 1252 
AATCAGGTT GC T GTCAGGGTGTGTGGGAGGCTCTGGT TTCCT GAGAAACCATCTGATCCTGCATTCAAAGTCATTCCTCTCTGGCTACTTCACTC T GCACATGAGAG 1359 
ATGCTCAGACT GTATCAAGTACTCAGAAAGAAGAGACTACCGGACACTCCTGRATCCAGCTCATGTACAGAACCATCTGAAACACCCAGTGGACCACAAT CT TGT 1466 
< .. . . . . . . . .  
GGTATGT GAAT T TCGATCATCATAGAAGGTGACCCCTCTCTATGTAGAATTTTTATTTTTC 1527 
. . . . . . . . . . . .  PMOR-2 
rMORtn 
K I D L F * 391 
AAA ATA GTA TTA TTT TGA AAAGGCATATA•ACAGAACTGGGAGAAGCACGCCAGAGATATTTTGTCACCATATGGCAAATGTAAGCCTAGAAACCAGGGT 1259 
ACC T GAT GCT GGT GCCAACCCCACT GACAACCACTT GTGCAAGAACATCCCATGC TGGTAGT TGTTGAACAGATTTCTTCATGACCAGAAGATCATTGACCTCTAA 1366 
GTT T GC TC TAGAGTTAGAACCT T GT T GATTACATCATTCAGACTCTGGGCAAGCTTCTCTCAAT G ACAAAGG 1437 
< . . . . . . . . . . . . . . . . . . . . . .  PMOR-3  
Fig. 1. The carboxy-termini of rMORI and rMOR1B. The deduced amino acid sequence is shown above the nucleotide sequence. Primers used for 
PCR (PMOR-I, PMOR-2 and PMOR-3) are marked by dashed lines with arrows. Note that both receptor variants hare identical nucleotide 
sequences up to amino acid 386. 
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Fig. 2. Displacement of [3H]DAMGO binding from rMOR1- and 
rMOR1B-expressing CHO-K1 cells by unlabeled ligands. Data from a 
representative experiment are presented for each ligand. ICs0 values 
were calculated by log probit analysis of two independent displacement 
curves. ICs0 (nM; rMOR1B/MOR1): DAMGO (5/5); naloxonazine (6/ 
5); DADLE (100/70); U-50488 (2000/3000); DPDPE (>10,000/ 
> 10,000). 
3.4. Second messenger coupling of receptor isoforms 
To test the ability of both variants to inhibit forskolin-stim- 
ulated cAMP accumulation, cells were incubated with increas- 
ing concentrations of DAMGO (1 nM to 1 pM) followed by 
the determination f the levels of cAMP (Fig. 4). Both rMORI 
and rMOR1B inhibit stimulated adenylate cyclase to the same 
extent (69 + 3% and 73 + 2%, respectively) and with a similar 
potency (ECso = 150 nM). Pretreatment of the cells with pertus- 
sis toxin (100 ng/ml) abolished the ability of the activated recep- 
tors to inhibit cAMP formation, indicating that both variants 
inhibit adenylate cyclase activity via pertussis toxin-sensitive G 
proteins (data not shown). However, a significant difference 
between the two variants in their desensitization behavior upon 
agonist reatment could be observed. Pretreatment of the cells 
with DAMGO (1/IM) attenuates the ability of the agonist o 
inhibit forskolin-stimulated adenylate cyclase faster in MOR1- 
than in MOR1B-expressing cells (Fig. 5). Thus, as early as 30 
min following preincubation with 1/,tM DAMGO, a significant 
reduction by the agonist of the inhibition of forskolin-induced 
cAMP levels (from 69 + 3% to 59 + 2%) was observed in cells 
expressing rMOR1. In contrast, in rMOR1B-expressing cells, 
pretreatment with DAMGO for 30 min, 1 h and 2 h had no 
influence on agonist-induced inhibition of stimulated adenylate 
cyclase; pretreatment with DAMGO for 5 h was required to 
obtain a significant effect (from 73 + 3% to 57 + 2%), indicat- 
ing that rMOR1B is less prone than rMOR1 to undergoing 
agonist-promoted desensitization (Fig. 5). After 24 h of prein- 
cubation with DAMGO, however, both receptors entirely lost 
their ability to inhibit adenylate cyclase. 
4. Discussion 
Our results provide evidence for the existence of another/1 
opioid receptor. Two subtypes of/.t opioid receptors (Pl and P2), 
which differ in their binding of morphine and enkephalin, have 
already been proposed [19]. However, the observation that 
rMOR1B binds to the ~tl-selective antagonist naloxonazine 
with a similar high affinity to rMOR1, excludes the possibility 
that rMOR1B encodes a/~2 receptor. 
There are an increasing number of reports demonstrating 
that splicing is a common mechanism to produce different 
C-termini of G protein-coupled receptors (GPC-Rs) [2~22]. 
Furthermore, the carboxy-terminal t il of GPC-Rs was shown 
to influence G protein selectivity [22] and/or the desenzitization 
characteristics of GPC-Rs [23]. Our group recently reported 
that the somatostatin receptor subtype 2 (SSTR 2) occurs in 
two isoforms. The spliced receptor SSTR 2B differed from the 
unspliced receptor (SSTR 2A) only at the C-terminus. The 
shorter form (SSTR 2B) was more resistant to agonist-induced 
desensitization than the longer form (SSTR 2A) [23]. In addi- 
tion, recent data provide evidence that the C-terminus also 
plays a crucial role in the desensitization process of other GPC- 
Rs. Thus, progressive truncation of the C-terminus of the rat 
substance P receptor attenuates agonist-induced desensitiza- 
tion [24]. Similarly, the platelet-activating factor (PAF) recep- 
M 1 2 3 4 5 6 7 8 9 10 11 12 13 
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Fig. 3. PCR analyses of rMOR1 (A) and rMOR1B (B) receptor transcripts from various rat brain tissues. Lanes: 1, bulbus olfactorius; 2, frontal 
cortex; 3, motor cortex; 4, striatum; 5, thalamus; 6, hypothalamus: 7, hippocampus; 8,tegmentum; 9,colliculi; 10, cerebellum; 11, pons; 12, medulla 
oblongata; 13, negative control. For amplification of rMOR1 the primer pair PMOR-I (sense) and PMOR-2 (antisense) were used, and for 
amplification of rMOR1B, PMOR-1 (sense), PMOR-3 (antisense) were used; see Fig. 1. M (marker), HaeIII-digested fragments of Fx 174 phage 
(in bp 1353, 1078, 872, 603, 310). 
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tor is rapidly desensitized in response to prolonged exposure to 
agonists, whereas a C-terminally truncated form of this recep- 
tor shows almost no desensitization characteristics [25]. Similar 
findings were noted in another mutant of the PAF receptor in 
which the serine and threonine residues in the carboxy tail were 
substituted with alanines [25]. This indicates that phosphoryla- 
tion of the C-terminal part of  the receptor by protein kinases 
(e.g. protein kinase A (PKA) or beta-adrenergic receptor kinase 
(flARK)) plays a crucial role in agonist-induced desensitization. 
It is noteworthy that within that region of the C-terminus in 
which rMOR 1 differs from rMOR1 B, one potential phospho- 
rylation site for f lARK is found (threonine-394). It remains to 
be clarified by mutation studies whether phosphorylation of 
this threonine is responsible for the faster desensitization of 
rMOR1B as compared to that of rMOR1, or if other mecha- 
nisms are also involved. 
While preparing this manuscript he isolation of another 
spliced variant of the human/2 opioid receptor was reported 
[26]. This isoform, in which the 3' terminal intron has not been 
removed, encodes a /2  receptor, which is eight amino acids 
shorter than hMOR1 and differs by four amino acids at the 
C-terminus (which showed no homology to rMOR1B). This 
human/2 receptor variant was shown to be expressed in SK-N- 
SH cells and in human brain. It would be interesting to know 
whether a similarly spliced isoform of MOR 1 may also occur 
in rats. Moreover, it is not unreasonable to assume that in 
various species everal alternatively spliced forms of the MOR 1 
receptor may exist which differ in amino acid composition at 
the very carboxy-terminus. It would be interesting to know 
whether they also differ in agonist-induced esensitization. 
Presently experiments are being carried out in our laboratory 
to search for additional C-terminally spliced isoforms of 
rMOR1. 
The existence of isoforms of MOR1 in brain which differ in 
agonist-induced esensitization may explain the well-known 
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Fig. 5. Time-courses ofagonist-induced desensitization f rMOR 1 and 
rMOR1B. Transfected CHO-K1 cells were preincubated at37°C with 
1 pM DAMGO for the indicated time intervals. After washing twice 
with 1 × PBS (phosphate buffered saline) cells were treated with fors- 
kolin or forskolin plus DAMGO, and cAMP levels were determined as 
described in section 2. Values represent means + S.E.M. from three 
separate measurements performed in triplicate. The asterisks (*) indi- 
cate significant difference (p < 0.05) from cells which were not preincu- 
bated with DAMGO (0). In addition, in the case of rMOR 1, significant 
differences could be observed at 30 rain vs. 10 min, 2 h vs. 1 h, 5 hr vs. 
2 h, and 24 h vs. 5 h after exposure to DAMGO. In the case 
of rMOR1B, significant differences were observed at 5 h vs. 2 h, and 
24 h vs. 5 h agonist exposure. C (control), forskolin treatment without 
DAMGO. 
observation that the development of tolerance to the various 
effects of morphine is different. Thus, a rapid tolerance to the 
analgesic effects of morphine is generally observed, whereas 
tolerance is much less pronounced in the case of the respiratory 
depressant effects of the opioid agonist. 
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